- A psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety.
- SUDS will be used as the primary outcome in future Phase 3 social anxiety disorder (SAD) clinical trials.
“We are excited to share the psychometric analysis we conducted of SUDS utilization in the Phase 2 PREVAIL trial of BNC210 in SAD, demonstrating it is a valid, reliable, and sensitive tool to assess anxiety,” commented Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “This presentation follows up the successful End-of-Phase 2 meeting we recently had with the
Key highlights from the poster presentation:
- BNC210 225 mg and 675 mg demonstrated reduced anxiety in patients with moderate to severe SAD in a public speaking challenge compared to placebo.
- BNC210 was well tolerated at both doses.
- Properties of the SUDS were evaluated to assess the SUDS’s fit for measuring the reduction in self-reported anxiety severity provoked by a public speaking challenge in patients with SAD:
- Sensitivity: No floor or ceiling effects were observed in the use of the SUDS in the PREVAIL study indicating it is highly sensitive to change over the entirety of its range.
- Reliability: The reliability of the SUDS at 20- and 30-minutes post-challenge was very high for both the placebo and the full population.
- Validity: Baseline SUDS scores demonstrated good convergent validity when compared with State-Trait Anxiety Inventory (STAI) scores.
SUDS will be used to assess the effect of BNC210 on reduction in anxiety during a public speaking challenge in the upcoming Phase 3 trial, which is anticipated to begin in Q1’24.
The poster presentation is available for viewing under the Publications webpage of the Company’s website.
FOR FURTHER INFORMATION PLEASE CONTACT:
General Company Secretary CoSec@bionomics.com.au | Investor Relations kgardner@lifesciadvisors.com | Investor Relations ccalabrese@lifesciadvisors.com |
About
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside
Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s plans to advance the development of its product candidates, the timing of achieving any development or regulatory milestones, and the comparability and potential of such product candidates, including to achieve any benefit or profile or any product approval or be effective. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the
Source:
2023 GlobeNewswire, Inc., source